Your browser is no longer supported. Please, upgrade your browser.
RTRX Retrophin, Inc. daily Stock Chart
RTRX [NASD]
Retrophin, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own1.30% Shs Outstand44.76M Perf Week-4.29%
Market Cap1.07B Forward P/E- EPS next Y-2.38 Insider Trans-7.88% Shs Float42.38M Perf Month16.13%
Income-110.90M PEG- EPS next Q-0.52 Inst Own- Short Float10.63% Perf Quarter2.10%
Sales187.30M P/S5.73 EPS this Y-36.20% Inst Trans0.38% Short Ratio14.42 Perf Half Y29.08%
Book/sh7.12 P/B2.94 EPS next Y-33.70% ROA-14.90% Target Price29.67 Perf Year85.40%
Cash/sh8.93 P/C2.35 EPS next 5Y20.00% ROE-36.40% 52W Range8.98 - 22.17 Perf YTD47.54%
Dividend- P/FCF- EPS past 5Y4.80% ROI-32.20% 52W High-5.48% Beta0.76
Dividend %- Quick Ratio7.10 Sales past 5Y44.10% Gross Margin96.70% 52W Low133.30% ATR0.98
Employees221 Current Ratio7.20 Sales Q/Q8.30% Oper. Margin-53.80% RSI (14)57.24 Volatility5.41% 4.50%
OptionableYes Debt/Eq0.00 EPS Q/Q37.00% Profit Margin-49.10% Rel Volume1.30 Prev Close21.08
ShortableYes LT Debt/Eq0.66 EarningsNov 05 AMC Payout- Avg Volume312.35K Price20.95
Recom1.40 SMA203.63% SMA508.05% SMA20021.84% Volume405,474 Change-0.62%
Sep-18-20Initiated Wedbush Outperform $33
Aug-24-20Initiated BofA Securities Buy $30
Jun-17-20Initiated BTIG Research Buy $25
Feb-25-20Downgrade Barclays Overweight → Equal Weight $19
Apr-22-19Initiated Barclays Overweight
Nov-19-18Initiated Nomura Buy $57
Aug-17-18Initiated Canaccord Genuity Buy $36
Nov-02-15Initiated JMP Securities Mkt Outperform $30
Jun-04-15Reiterated Deutsche Bank Buy $52 → $55
May-15-15Initiated Avondale Mkt Outperform
Apr-28-15Initiated Deutsche Bank Buy $50
Oct-23-20 07:26AM  
Oct-22-20 04:01PM  
Oct-21-20 04:30PM  
Oct-14-20 05:00PM  
Oct-09-20 04:01PM  
Sep-28-20 08:52PM  
Sep-21-20 08:00AM  
Sep-18-20 09:31AM  
Sep-14-20 05:00PM  
Aug-28-20 10:56AM  
Aug-24-20 09:34AM  
Aug-03-20 04:30PM  
Jul-30-20 06:40PM  
04:01PM  
Jul-23-20 12:33PM  
Jul-20-20 06:37PM  
Jul-16-20 04:30PM  
Jun-26-20 08:21AM  
Jun-25-20 08:42AM  
Jun-19-20 08:00AM  
Jun-17-20 01:55PM  
Jun-08-20 10:02PM  
04:01PM  
May-27-20 04:30PM  
May-12-20 01:01PM  
May-11-20 06:05PM  
04:01PM  
Apr-28-20 12:33PM  
Apr-27-20 04:30PM  
Apr-11-20 10:25AM  
Apr-09-20 04:30PM  
Mar-18-20 10:01AM  
Mar-09-20 08:00AM  
Mar-08-20 09:01PM  
Feb-28-20 08:00AM  
Feb-24-20 04:01PM  
Feb-19-20 04:30PM  
Feb-13-20 05:00PM  
Feb-11-20 12:45PM  
Feb-10-20 04:30PM  
Jan-13-20 06:59AM  
Dec-18-19 07:59AM  
Dec-12-19 10:54AM  
Dec-10-19 03:57PM  
Nov-15-19 02:13PM  
Nov-14-19 04:30PM  
Nov-08-19 10:04AM  
Nov-07-19 10:21AM  
09:17AM  
Oct-30-19 07:05PM  
04:01PM  
Oct-28-19 06:04PM  
Oct-23-19 10:34AM  
Oct-16-19 04:30PM  
Oct-11-19 04:05PM  
Oct-01-19 04:30PM  
11:31AM  
Sep-26-19 04:30PM  
Aug-28-19 10:34AM  
Aug-23-19 07:38AM  
Aug-22-19 04:33PM  
04:15PM  
02:00PM  
10:42AM  
07:59AM  
07:18AM  
06:32AM  
06:13AM  
06:00AM  
Aug-19-19 09:55AM  
Aug-14-19 04:25AM  
Aug-07-19 08:25AM  
Aug-06-19 06:45PM  
Jul-31-19 04:30PM  
09:59AM  
Jul-30-19 10:38AM  
Jul-23-19 04:30PM  
Jul-18-19 10:33AM  
Jun-29-19 08:25AM  
Jun-28-19 06:15AM  
Jun-25-19 02:30PM  
02:28PM  
Jun-21-19 09:06AM  
Jun-20-19 05:13PM  
04:33PM  
Jun-18-19 04:30PM  
Jun-03-19 12:33PM  
May-31-19 05:41PM  
02:55PM  
May-30-19 04:30PM  
May-13-19 06:30PM  
08:00AM  
May-08-19 03:24PM  
May-07-19 06:35PM  
05:26PM  
04:01PM  
02:30PM  
10:55AM  
Apr-30-19 10:32AM  
09:30AM  
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Heerma PeterChief Commercial OfficerOct 05Sale19.352,18842,33842,329Oct 05 08:31 PM
Heerma PeterChief Commercial OfficerOct 02Sale18.902,18841,35344,517Oct 05 08:31 PM
Clague LauraChief Financial OfficerSep 23Sale18.481,50027,72019,473Sep 23 08:00 PM
Rosenberg Noah L.Chief Medical OfficerSep 23Sale18.4875013,86027,555Sep 23 08:00 PM
REED ELIZABETH ESVP, GC & Corporate SecretarySep 23Sale18.481,50027,72025,431Sep 23 08:00 PM
ROTE WILLIAM E.Senior Vice President, R&DSep 23Sale18.481,50027,72024,086Sep 23 08:00 PM
Rosenberg Noah L.Chief Medical OfficerSep 22Sale18.5975013,94328,305Sep 22 09:20 PM
ROTE WILLIAM E.Senior Vice President, R&DSep 22Sale18.591,50027,88525,586Sep 22 09:20 PM
REED ELIZABETH ESVP, GC & Corporate SecretarySep 22Sale18.591,50027,88526,931Sep 22 09:18 PM
Clague LauraChief Financial OfficerSep 22Sale18.591,50027,88520,973Sep 22 09:18 PM
Dube Eric MChief Executive OfficerSep 21Sale19.2810,805208,31994,695Sep 22 09:15 PM
ASELAGE STEVEDirectorAug 05Sale19.682,50049,200236,232Aug 06 04:07 PM
Rosenberg Noah L.Chief Medical OfficerJul 28Sale20.4987017,82626,055Jul 30 07:48 PM
ASELAGE STEVEDirectorJun 25Sale20.0010,000200,000238,732Jun 29 09:02 PM
ASELAGE STEVEDirectorMay 14Sale15.093,06246,206245,732May 14 08:59 PM
ASELAGE STEVEDirectorMay 13Sale16.414,06366,674248,794May 14 08:59 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMay 12Sale17.071,05217,96025,431May 13 09:00 PM
ASELAGE STEVEDirectorMay 12Sale17.161,00017,160252,857May 14 08:59 PM
Rosenberg Noah L.Chief Medical OfficerMay 12Sale16.985278,95126,728May 13 09:00 PM
Clague LauraChief Financial OfficerMay 12Sale17.111,77730,40119,473May 13 09:00 PM
ROTE WILLIAM E.Senior Vice President, R&DMay 12Sale17.091,33922,88523,494May 13 09:00 PM
ROTE WILLIAM E.Senior Vice President, R&DMay 11Sale14.9581312,15424,833May 13 09:00 PM
Clague LauraChief Financial OfficerMay 11Sale14.951,25018,68821,250May 13 09:00 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMay 11Sale14.955257,84926,483May 13 09:00 PM
ASELAGE STEVEDirectorMay 05Sale15.882,50039,700253,857May 06 04:09 PM
ROTE WILLIAM E.Senior Vice President, R&DMar 10Sale14.873,25048,32825,646Mar 12 07:45 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryMar 10Sale15.023,50052,57027,008Mar 12 07:44 PM
Clague LauraChief Financial OfficerMar 10Sale15.024,00060,08022,500Mar 12 07:43 PM
Rosenberg Noah L.Chief Medical OfficerMar 05Sale15.361,79027,48727,255Mar 09 09:05 PM
ASELAGE STEVEDirectorMar 05Sale15.364,35966,939256,357Mar 09 09:03 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 18Sale16.551,25020,68825,646Feb 19 04:05 PM
ROTE WILLIAM E.Senior Vice President, R&DFeb 14Sale16.721,25020,90026,896Feb 19 04:05 PM
ASELAGE STEVEDirectorFeb 05Sale16.622,50041,550248,466Feb 07 07:38 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 08Sale15.1475011,35518,008Jan 08 09:01 PM
Dube Eric MChief Executive OfficerJan 08Sale15.143,75056,77542,500Jan 08 08:49 PM
Dube Eric MChief Executive OfficerJan 07Sale13.943,75052,27546,250Jan 08 08:49 PM
REED ELIZABETH ESVP, GC & Corporate SecretaryJan 07Sale13.9475010,45518,758Jan 08 09:01 PM
ASELAGE STEVEDirectorNov 29Sale13.915,00069,553250,966Nov 29 09:27 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.